Literature DB >> 6735997

Tyramine studies and the safety of MAOI drugs.

G M Simpson, K White.   

Abstract

A major source of concern in using MAOIs is the risk of hypertensive crises, often called the "cheese effect" and thought to represent a drug-induced enhancement of the tyramine pressor effect. Several approaches to reduction of this risk are being explored, including use of inhibitors specific for the B vs. the A type of the enzyme, coadministration of tricyclic with MAOI, and development of reversible inhibitors which might be competitively displaced by tyramine. Such approaches require assessment of sensitivity to tyramine, usually given by the intravenous route. The oral tyramine pressor test, while cumbersome and in need of technical refinement, represents a significantly closer laboratory analogue to the clinical situation.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6735997

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  5 in total

1.  Monoamine oxidase inhibitor overdose.

Authors:  M Thorp; D Toombs; B Harmon
Journal:  West J Med       Date:  1997-04

Review 2.  Monoamine oxidase inhibitors revisited.

Authors:  D G Wells; A R Bjorksten
Journal:  Can J Anaesth       Date:  1989-01       Impact factor: 5.063

3.  Oral tyramine pressor test and the safety of MAO inhibitor drugs.

Authors:  R Schulz; P R Bieck
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

4.  Intravenous amine pressor tests in healthy volunteers. Within- and between subject variances and sex differences.

Authors:  I W Reimann; L Firkusny; K H Antonin; P R Bieck
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

5.  Influence of food on the tyramine pressor effect during chronic moclobemide treatment of healthy volunteers.

Authors:  C Audebert; O Blin; S Monjanel-Mouterde; P Auquier; A M Pedarriosse; J Dingemanse; A Durand; J P Cano
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.